SBH
VRTX icon

Segall Bryant & Hamill’s Vertex Pharmaceuticals VRTX Stock Holding History

Segall Bryant & Hamill’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.4M Sell
37,072
-1,001
-3% -$444K 0.22% 167
2026
Q1 		$17M Sell
38,073
-1,746
-4% -$814K 0.24% 154
2025
Q4 		$18.1M Sell
39,819
-1,152
-3% -$497K 0.24% 149
2025
Q3 		$16M Sell
40,971
-1,357
-3% -$567K 0.21% 166
2025
Q2 		$18.8M Sell
42,328
-10,494
-20% -$4.84M 0.26% 127
2025
Q1 		$25.6M Sell
52,822
-3,413
-6% -$1.59M 0.39% 76
2024
Q4 		$22.6M Sell
56,235
-1,590
-3% -$737K 0.31% 100
2024
Q3 		$26.9M Buy
+57,825
New +$27.8M 0.37% 88
2023
Q3 		– Sell
-876
Closed -$308K – 700
2023
Q2 		$308K Buy
876
+14
+2% +$4.72K ﹤0.01% 638
2023
Q1 		$271K Hold
862
– – ﹤0.01% 655
2022
Q4 		$248K Hold
862
– – ﹤0.01% 673
2022
Q3 		$250K Hold
862
– – ﹤0.01% 680
2022
Q2 		$243K Hold
862
– – ﹤0.01% 689
2022
Q1 		$225K Buy
+862
New +$205K ﹤0.01% 716
2021
Q3 		– Sell
-2,385
Closed -$480K – 799
2021
Q2 		$480K Buy
2,385
+376
+19% +$78.6K ﹤0.01% 616
2021
Q1 		$431K Buy
2,009
+18
+0.9% +$3.95K ﹤0.01% 676
2020
Q4 		$469K Buy
1,991
+174
+10% +$39.9K 0.01% 587
2020
Q3 		$493K Buy
1,817
+946
+109% +$261K 0.01% 547
2020
Q2 		$253K Hold
871
– – ﹤0.01% 717
2020
Q1 		$208K Buy
+871
New +$200K ﹤0.01% 738
2018
Q4 		– Sell
-1,136
Closed -$219K – 882
2018
Q3 		$219K Buy
+1,136
New +$202K ﹤0.01% 808

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Segall Bryant & Hamill's VRTX Position: Q2 2026 in Review

Segall Bryant & Hamill reduced its Vertex Pharmaceuticals (VRTX) stake by 2.6% in Q2 2026, selling an estimated $444K and leaving 37,072 shares worth $18.4M. The position accounts for 0.22% of the portfolio, ranked #167.

Segall Bryant & Hamill first reported a position in VRTX in Q3 2018 and has held it in 21 quarters since. The position peaked at $26.9M in Q3 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Segall Bryant & Hamill held 37,072 shares of Vertex Pharmaceuticals worth $18.4M as of Q2 2026.
  • Segall Bryant & Hamill sold 1,001 Vertex Pharmaceuticals shares in Q2 2026, an estimated $444K.
  • Vertex Pharmaceuticals made up 0.22% of Segall Bryant & Hamill's portfolio in Q2 2026, its #167 holding.
  • Segall Bryant & Hamill first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 21 quarters since.
  • Segall Bryant & Hamill's Vertex Pharmaceuticals position peaked at $26.9M in Q3 2024.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.